1. Introduction {#sec0005}
===============

Novel coronavirus disease 2019 (COVID-19), which emerged in Wuhan, China, in December 2019, has not only swept across China but also rapidly spread to almost all countries and regions around the world \[[@bib0005],[@bib0010]\]. The World Health Organization (WHO) named pneumonia caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) COVID-19 and declared it a global pandemic \[[@bib0015]\]. As of June 20, 2020, approximately 8,525,042 cases have been confirmed worldwide, and 456,973 deaths have occurred \[[@bib0020]\].

The main manifestation of COVID-19 is acute respiratory infection, and the renal, cardiovascular, digestive, blood and nervous systems may be simultaneously involved \[[@bib0025],[@bib0030]\]. According to a report from the Chinese Center for Disease Control and Prevention, the case-fatality rate was 2.3 % in 44,672 patients with confirmed cases of COVID-19, and all cases of death involved critical patients \[[@bib0035]\]. Therefore, the identification of predictors of severe infection and mortality is essential for guiding clinical treatment and intervention.

Acute kidney injury (AKI) is one of the most important complications of COVID-19 \[[@bib0040]\]. According to the definition of AKI by the Kidney Disease: Improving Global Outcomes (KDIGO) criteria, the incidence of AKI in hospitalized Chinese adults was 11.6 % and rose to 50 % for those in the intensive care unit (ICU), indicating that the incidence of COVID-19-induced AKI is highly variable to date \[[@bib0045], [@bib0050], [@bib0055]\]. Currently, several studies have shown that the fatality rate of COVID-19 patients with AKI is incredibly high, ranging from 8% to 23 % \[[@bib0060],[@bib0065]\]. A previous study indicated that 6.7 % of patients with SARS might develop AKI, and the mortality rate of those with AKI is 91.7 % \[[@bib0070],[@bib0075]\]. This finding indicates that clinicians must pay more attention to COVID-19 patients complicated with AKI. The development of AKI in COVID-19 patients is a critical prognostic factor for survival, but, unlike other known prognostic factors, AKI is possibly curable by interventions. In this article, we performed a systematic review and meta-analysis to explore the correlation between AKI and disease severity and fatality in patients with COVID-19 and to provide reliable evidence for improving the treatment and control of COVID-19.

2. Methods {#sec0010}
==========

Our systematic literature search was performed according to the Meta-Analysis of Observational Studies in Epidemiology (MOOSE) guidelines \[[@bib0080]\]and was conducted using a predetermined protocol according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement \[[@bib0085]\].

2.1. Search strategy {#sec0015}
--------------------

The PubMed, Web of Science, ScienceDirect, MedRxiv and COVID-19 academic research communication platforms (articles in Chinese, <http://medjournals.cn/2019NCP/index.do>) were used to search for articles published up until June 20, 2020, without applying language restrictions.

The following keywords were used alone and in combination: ("coronavirus disease 2019" OR "COVID-19" OR "novel coronavirus pneumonia" OR "2019-nCoV" OR "SARS-CoV-2") and ("kidney" OR "renal") and ("clinical characteristics" OR "clinical features" OR "clinical outcome" OR "epidemiological characteristics"). The titles, abstracts and full texts of all documents identified with the search criteria were assessed, and those reporting AKI in COVID-19 patients with and without fatality and/or disease severity were included in this meta-analysis. The reference lists of all studies were also analyzed to identify additional eligible studies.

2.2. Study selection {#sec0020}
--------------------

Two investigators (MJS and JYL) independently scanned all the titles and abstracts to identify studies that met the inclusion criteria, and they extracted data from these studies. Any discrepancies between the reviewers were resolved by discussion with a third reviewer (FL). Studies were regarded as eligible for inclusion in this meta-analysis if they reported AKI in adult laboratory-confirmed COVID-19 patients, with and without fatality and/or disease severity data. The definition of severe COVID-19 refers to the guidelines on the diagnosis and treatment of novel coronavirus pneumonia (trial seventh edition) \[[@bib0090]\]. AKI was identified and classified based on the highest serum creatinine (Scr) level according to the KDIGO definition and staging system \[[@bib0095]\].

2.3. Data collection {#sec0025}
--------------------

The two investigators (MJS and JYL) who performed the literature search also independently extracted the data from the included studies. Any disagreements were resolved with a third investigator (FL) or by consensus. Data were collected and entered into a spreadsheet. We extracted the following variables: author, study period, location, age, sex, number of participants categorized as severe or non-severe, fatality rate, and the prevalence of clinical symptoms and comorbidities.

2.4. Statistical analysis {#sec0030}
-------------------------

A meta-analysis was performed on the retrievable data, and the odds ratio (OR) and its 95 % confidence interval (CI) were estimated for AKI in COVID-19 patients with or without severe infection or fatality.

The meta-analysis was performed using R version 3.6.3 (R Foundation for Statistical Computing, Vienna, Austria). The Mantel-Haenszel method (statistical method) and a random-effects model (analysis model) were used to assess the outcomes. The incidence of AKI is expressed as a proportion and 95 % CI using a random-effects model, and the restricted maximum-likelihood estimator.

Heterogeneity was evaluated using the chi-squared test and the *I* ^2^ statistic. For the chi-squared test, significant heterogeneity among studies was indicated with a Cochran's *Q* p-value of \<0.10. *I* ^2^ values of 25 %, 25--50 %, or 50 % indicated low, moderate, or high heterogeneity, respectively \[[@bib0100]\]. If there was high heterogeneity, several sensitivity analyses were conducted to inspect the influence of individual studies by removing each trial independently using a random effects model (leave-one-out approach) \[[@bib0105]\]. If only the median and interquartile range (Q25, Q75) were reported, we used simple and elementary inequalities to estimate the mean and variance for the trials \[[@bib0110]\].

Publication bias was evaluated qualitatively by the asymmetry of the funnel plot and quantitatively by Egger's test, and the significance of asymmetry was explored using visual inspection and tested with a rank correlation test based on Kendall's **τ**. We used the Newcastle-Ottawa Scale (NOS) to further evaluate the quality of the observational studies, and an NOS score\>7 was considered good quality \[[@bib0115]\].

3. Results {#sec0035}
==========

The flow of studies through the analysis is presented in [Fig. 1](#fig0005){ref-type="fig"} . A total of 40 eligible studies involving 24,527 patients were ultimately enrolled in our study. The characteristics of the included studies are described in [Table 1](#tbl0005){ref-type="table"} , and the treatment and clinical outcome of the patients are described in [Table 2](#tbl0010){ref-type="table"} . All articles included in the meta-analysis were high-quality according to the NOS tool.Fig. 1Flow diagram of literature selection.Fig. 1Table 1Characteristics of the 40 studies included in the meta-analysis.Table 1StudyStudy periodLocationOutcomeNOS scoreNo. of patientsAgeMale (n, %)Comorbidity (n, %)CKDHypertensionDiabetesCOPDCVDCancerWang L et al. \[[@bib0120]\]Jan 1∼ Feb 6, 2020Renmin Hospital of Wuhan UniversityFatality833969 (65,76)166 (49.0)13 (3.8)138 (40.8)54 (16.0)21 (6.2)53 (15.7)15 (4.4)Yang X et al. \[[@bib0125]\]Dec 24, 2019 ∼ Jan 26, 2020Wuhan Jin Yin-Tan HospitalFatality85259.7 ± 13.335 (67)NANA9 (17)4 (8)5 (10)2 (4)Zhou F et al. \[[@bib0130]\]Dec 29, 2019 ∼ Jan 31, 2020Wuhan Jin Yin-Tan Hospital and Pulmonary HospitalFatality819156 (46,67)119 (62)2 (1)58 (30)36 (19)6 (3)23 (8)2 (1)Chen T et al. \[[@bib0135]\]Jan 13 ∼ Feb 28, 2020Tongji HospitalFatality827462 (44,70)171 (62)4 (1)93 (34)47 (17)18 (7)24 (9)7 (3)Luo X et al. \[[@bib0140]\]Jan 30 ∼ Feb 25, 2020Eastern Campus of Renmin Hospital of Wuhan UniversityFatality840356 (39,68)193 (47.9)7 (1.7)113 (28.0)57 (14.1)28 (6.9)75 (18.6)NAXiao G et al. \[[@bib0145]\]Jan 5 ∼ Mar 8, 2020Nan Fang HospitalFatality828762 (51,70)160 (55.7)5 (2)87 (30)45 (16)16 (6)33 (12)8 (3)Deng Y et al. \[[@bib0150]\]Jan 1 ∼ Feb 21, 2020Two tertiary hospitals in WuhanFatality722569 (62,74)124 (55.1)NA58 (25.8)26 (11.6)25 (11.1)17 (7.6)8 (3.6)Safiya R et al. \[[@bib0155]\]Mar 5∼ Apr 8, 2020New York CityFatality7570063 (52,75)3437 (60.3)268 (5)3026 (56.6)1808 (33.8)287 (5.4)595 (11.1)320 (6)Peng Z et al. \[[@bib0160]\]Jan 1 ∼ Feb 10, 2020Xishui People's HospitalFatality710751 (36,65)57 (53.3)3 (2.8)26 (24.3)11 (10.3)3 (2.8)13 (12.1)NAAlberto M et al. \[[@bib0165]\]Feb 25 ∼ Apr 19, 2020La Paz University of Spain the HospitalFatality7222661 (46,78)1074 (48.2)174 (7.8)920 (41.3)381 (17.1)153 (6.9)429 (19.3)133 (6.0)Wang Y et al. \[[@bib0170]\]Jan 25 ∼ Feb 25, 2020Tongji hospitalFatality734464 (52,72)179 (52.0)NA141 (41.0)64 (18.6)16 (4.7)40 (11.6)NACao J et al. \[[@bib0175]\]Jan 3 ∼ Feb 1, 2020Wuhan University Zhong nan HospitalFatality710254(37,67)49 (48.0)4 (3.9)28 (27.5)11 (10.8)10 (9.8)5 (4.9)4 (3.9)Zhang J et al. \[[@bib0180]\]Jan 1 ∼ Feb 1, 2020Wuhan Fourth HospitalFatality739456 (42,67)186 (47.2)NA115 (29.2)47 (11.9)23 (5.8)38 (9.6)24 (6.1)Chen F et al. \[[@bib0185]\]Jan 1 ∼ Feb 15, 2020Central Hospital of WuhanFatality766055 (34,68)295 (44.7)NA230 (34.8)114 (17.3)43 (6.5)67 (10.2)NAJerald P et al. \[[@bib0190]\]NAAfrican American patients from underserved socioeconomic groups.Fatality722365.9 ± 14.9115 (52)39 (17.5)180 (72)104 (47)27 (12.1)35 (11.2)NAJeong Hoon et al. \[[@bib0305]\]Feb 17 ∼ Mar 22, 2020The Kyungpook National University Hospital Daegu, South KoreaFatality716067 (24,92)86 (53.8)NA77 (48.1)50 (31.2)16 (10)21 (13.1)26 (16.3)Pei G et al. \[[@bib0200]\]Jan 28 ∼ Feb 9, 2020Tongji Hospital of Sino-French New City DistrictNon-severe/severe, Fatality733356.3 ± 13.4182 (54.7)NA107 (32.2)76 (22.9)NANANAXu S et al. \[[@bib0205]\]Jan 1 ∼ Feb 20, 2020The Second Affiliated Hospital of Anhui Medical UniversityNon-severe/severe, Fatality7355NA193 (54.4)NA125 (35.2)147 (41.4)NANANAJamie S et al. \[[@bib0210]\]Mar 1 ∼ Apr 5, 202013 Northwell Health hospitalsNon-severe/severe8544964 (52, 75)3317 (60.9)NA3037 (55.7)1797 (33.0)296 (5.4)600 (11.0)327 (6.0)Abdullah A et al. \[[@bib0215]\]Feb 24 ∼ May 24, 2020Jaber Al-Ahmad Hospital, Kuwait.Non-severe/severe, Fatality841745.4 ± 17.2262 (63)14 (3.4)123 (29.5)97 (23.3)1 (0.2)39 (9.4)12 (2.9)Sinan T et al. \[[@bib0220]\]Mar 15 ∼ May 1, 2020Cerrahpasa Medical Faculty, TurkeyNon-severe/severe, Fatality733655.0 ± 15.9192 (57.1)NA120 (35.7)63 (18.8)19 (5.7)NA31 (10.1)Li X et al. \[[@bib0225]\]Jan 26 ∼ Feb 5, 2020Sino-French New City Branch of Tongji HospitalNon-severe/severe854860 (48, 69)279 (50.9)10 (1.8)166 (30.3)83 (15.1)17 (3.1)34 (6.2)24 (4.7)Cheng Y et al. \[[@bib0065]\]Jan 28 ∼ Feb 11, 2020Tongji HospitalNon-severe/severe770163 (50,71)367 (52.4)14 of 698 (2.0)233 of 698 (33.4)100 of 698 (14.3)13 of 698 (1.9)NA32 of 698 (4.6)Wan S et al. \[[@bib0230]\]Jan 23 ∼ Feb 8, 2020Three Gorges Central HospitalNon-severe/severe813547 (36, 55)72 (53.3)NA13 (9.6)12 (8.9)1 (0.7)7 (5.2)4(3.0)Huang C et al. \[[@bib0025]\]Dec 16, 2019 ∼ Jan 2, 2020.Wuhan Jin Yin-tan hospitalNon-severe/severe84149 (41,58)30 (73)NA6 (15)8 (20)1 (2)6 (15)1 (2)Guan W et al. \[[@bib0235]\]Dec 11, 2019 ∼Jan 31, 2020cases outside Hubei province of Wuhan Jin Yin-Tan HospitalNon-severe/severe8109947 (35,58)610(58.1)8 (0.7)165 (15.0)81 (7.4)12 (1.1)27 (2.5)10 (0.9)Yan S et al. \[[@bib0240]\]Jan 22 ∼ Mar 14, 2020Hainan provinceNon-severe/severe816851 (36,62)81 (48.2)1 (0.6)24 (14.3)12 (7.1)2 (1.2)12 (7.1)2 (1.2)Zhao W et al. \[[@bib0245]\]Jan 21 ∼ Feb 8, 2020Beijing YouAn Hospital, Beijing,Non-severe/severe77752 ± 2034 (44.2)5 (6.5)16 (20.8)6 (7.8)6 (7.8)9 (11.7)4 (5.2)Wang D et al. \[[@bib0250]\]Jan 1 ∼ Jan 28, 2020Zhongnan Hospital of WuhanNon-severe/severe813856 (42,68)75 (54.3)4 (2.9)43 (31.2)14 (10.1)4 (2.9)20 (14.5)10 (7.2)Zhang G et al. \[[@bib0255]\]Jan 28 ∼ Feb 20, 2020Zhongnan Hospital of WuhanNon-severe/severe822155 (39,67)108 (48.9)6 (2.7)54 (24.4)22 (10.0)6 (2.7)22 (10.0)9 (4.1)Hu L et al. \[[@bib0260]\]Jan 8 ∼ Mar 10, 2020Tianyou Hospital, Affiliated to Wuhan University of Science and TechnologyNon-severe/severe732361 (23,91)166 (51.4)7 (2.2)105 (32.5)47 (14.6)6 (1.9)41 (12.7)5 (1.5)Shi P et al. \[[@bib0265]\]Jan 27 ∼ Mar 7, 20209 cities of Shanxi provinceNon-severe/severe713446 (34,58)65 (48.5)020 (14.9)9 (6.7)5 (3.7)6 (4.5)5 (3.7)Li Z et al. \[[@bib0270]\]Jan 6 ∼ Feb 21, 20204 hospitals in Hubei province and Chongqing cityNon-severe/severe819357 (46,67)95 (49)10 (5)NANA27 (14)70 (36)NALi Q et al. \[[@bib0275]\]Jan 20 ∼ Feb 29, 2020Shanghai Public Health Clinical CenterNon-severe/severe732551 (36,64)167 (51.4)4 (1.2)78 (24)30 (9.2)4 (1.2)18 (5.5)3 (0.9)Zhao XY et al. \[[@bib0280]\]Jan 16 ∼ Feb 10, 2020Jingzhou Central HospitalNon-severe/severe8914649 (53.8)1 (1)18 (19.8)3 (3.3)1(1)NA3 (3.3)Yang L et al. \[[@bib0285]\]Jan 30 ∼ Feb 8, 2020Yichang Central People\'s HospitalNon-severe/severe720055.0 ± 17.198 (49)3 (1.5)45 (22.5)21 (10.5)7 (3.5)11 (5.5)4 (2)Yang Q et al. \[[@bib0290]\]Jan 28 ∼ Feb 12, 2020Wuhan Third HospitalNon-severe/severe713656 (44,64)66 (48.5)4 (2.9)36 (27.1)20 (147)NA9 (6.6)4 (2.9)Michael G et al. \[[@bib0295]\]Mar 11 ∼ Apr 6, 2020NYP/CUIMC electronic health recordNon-severe/severe8100063 (50,75)596 (59.6)137 (13.7)601 (60.1)372 (37.2)66 (6.6)131 (13.1)67 (6.7)Antoni S et al. \[[@bib0300]\]Feb 20 ∼ Apr 20, 2020three urban primary healthcare centers, Barcelona, SpainNon-severe/severe732256.7 ± 17.8161 (50)31 (9.6)109 (33.9)46 (14.3)19 (5.9)25 (7.8)37 (11.5)Kyung Soo et al. \[[@bib0195]\]Up to March 29, 2020Yeungnam University Medical Center, Daegu, KoreaNon-severe/severe89855.4 ± 17.138 (38.8)NA30 (30.6)9 (9.2)3 (3.1)11 (11.2)4 (4.1)[^2]Table 2Treatment and clinical outcome of patients with COVID-19 in the meta-analysis.Table 2StudyAKI (n, %)CSR (n, %)CFR (n, %)Treatment (n, %)Laboratory findingsAntiviralGlucocorticoidsOxygen inhalationNIVIMVECMOCRRTBUN, mmol/LScr, μmol/LProteinuria (n, %)Hematuria (n, %)UA, μmol/LWang L et al. \[[@bib0120]\]27 (8.1)239 (70.5)65 (19.2)NANANANANANANA5.5 (4.0,8.0)61.0 (50.0, 76.0)NANANAYang X et al. \[[@bib0125]\]15 (28.8)52 (100)32 (61.5)23 (44)30 (58)33 (63.5)29 (56)22 (42)6 (11.5)9 (17)NA76.3 ± 27.4NANANAZhou F et al. \[[@bib0130]\]28 (14.7)66 (35)54 (28)41 (21)57 (30)41 (21)26 (14)32 (17)3 (2)10 (5)NA\>133 μmol/L (4%)NANANAChen T et al. \[[@bib0135]\]29 (11.7)NA113 (41.2)236 (86)217 (79)251 (92)102 (37)17 (6)1 (0.4)3 (1)4.9 (3.5, 7.9)76.0 (58.0,94.0)100 of 166 (60)84 of 166 (51)NALuo X et al. \[[@bib0140]\]57 (14. 1)205 (50.9)100 (24.8)394 (97.8)166 (41.2)106 (26.3)56 (13.9)23 (5.7)NA39 (9.7)NA69.0 (60.0, 86.0)NANANAXiao G et al. \[[@bib0145]\]55 (19.2)124 (43)19 (6.6)NANANANANANANANANANANANADeng Y et al. \[[@bib0150]\]20 (8.9)104 (46.2)109 (48.4)185 (82.2)88 (39.1)115 (51.1)68 (30.2)21 (9.3)2 (0.9)NANANANANANASafiya R et al. \[[@bib0155]\]523 (22.2)373 (14.2)553 (21)NANANA320 (12.2)NANA81 (3.2)NANANANANAPeng Z et al. \[[@bib0160]\]14 (13.1)11 (10.3)19 (17.8)105 (98.1)62 (57.9)80 (74.8)7 (6.5)17 (15.9)3 (2.8)NA4.2 (3.2, 5.6)71 (60,86)NANANAAlberto M et al. \[[@bib0165]\]173 (7.8)237 (7.6)460 (14.7)NANANANANANANANA0.89 (0.8, 1) mg/dLNANANAWang Y et al. \[[@bib0170]\]86 (25.0)133 (38.7)344 (100)283 (82.3)225 (65.4)35 (10.2)34 (9.9)100 (29.1)2 (0.6)9 (2.6)5.3 (3.8,8.3)74 (58,93)NANANACao J et al. \[[@bib0175]\]20 (19.6)18 (17.6)17(16.7)100 (98.0)51 (50.0)76 (74.5)5 (4.9)14 (13.7)3 (2.9)6 (5.9)4.33 (3.45,5.46)NANANA269 (228,347)Zhang J et al. \[[@bib0180]\]37 (9.5)NA22 (5.6)NANANANANANANA4.35 (3.45,5.68)69.0 (55.6,83.0)NANANAChen F et al. \[[@bib0185]\]36 (5.5)151/643 (23.5)82 (12.4)NANANANANANANA4.2 (3.3,5.6)65.1 (52.0,79.5)NANANAJerald P et al. \[[@bib0190]\]110 (49.3)NA44 (19.7)NA49 (22.0)NANA48 (21.5)NA18 (8)NANANANANAJeong Hoon et al. \[[@bib0305]\]30 (18.8)20/30 (66.7)44 (27.5)29/30 (96.7)18/30 (60.0)29/30 (96.7)NA16/30 (53.3)1/30 (3.3)5/30 (16.7)23.7 (15.7,32.0)/30 mg/dL1.1 (0.8,1.6) /30 mg/dLNANANAPei G et al. \[[@bib0200]\]35 (10.5)56 (16.8)29 (8.7)NANANANANANANA4.7 (3.5, 5.9)74.0 (61.0, 89.0)177 (89.4)109 (55.0)NAXu S et al. \[[@bib0205]\]56 (15.8)32 (9.0)32 (9.0)NANANANANANANA4.9 (1.1, 37.5)72.4 (32.0, 355.0)NANA259.7 (29.07, 677.07)Jamie S et al. \[[@bib0210]\]1993 (36.6)1395 (25.6)888 (16.3)NANANANANA10 (0.2)NANA1.01 (0.8,1.3) mg/dLNANANAAbdullah A et al. \[[@bib0215]\]41 (9.8)82 (19.7)60 (14.6)100 (24.0)6 (1.4)NANANA3 (0.7)NA3.33 (2.83--4.03)61.46 (51.5--75.86)NANANASinan T et al. \[[@bib0220]\]61 (18.2)59 (17.6)43 (12.8)NA21 (6.3)NANANANANA37.6 ± 31.0 mg/dL1.2 ± 1.2 mg/dLNANA5.1 ± 2.0 mg/dLLi X et al. \[[@bib0225]\]95 (17.3)269 (49.1)90 (16.5)NA341 (62.2)355 (64.8)78 (14.2)25 (4.6)NA2 (0.4)\>7.5 mmol/L 85 of 539 (15.8%)\>85 μmol/L 146 of 539 (27.1%)200/300 (60.6)NANACheng Y et al. \[[@bib0065]\]101 (14.4)297 (42.4)113 (16.1)658 (93.9)387 (55.2)NANA97 (13.4)NANA5.7 ± 3.977 ± 31194 of 442(43.9 %)118 of 442 (26.7 %)NAWan S et al. \[[@bib0230]\]10 (7.4)40 (29.6)1 (0.7)135 (100)36 (26.7)90 (66.7)34 (25.2)1 (0.7)05 (3.7)NA66(57.8,74.5)NANANAHuang C et al. \[[@bib0025]\]3 (7.3)13 (31.7)6 (15)38 (93)9 (22)27 (66)10 (24)2 (5)2 (5)3 (7)NA74.2 (57.5,85.7)NANANAGuan W et al. \[[@bib0235]\]6 (0.5)173 (15.7)55 (5.0)393 (35.8)204 (18.6)454 (41.3)56 (5.1)25 (2.3)5 (0.5)9 (0.8)NA\>133 μmol/L 12 of 752(1.6 %)NANANAYan S et al. \[[@bib0240]\]6 (3.6)36 (21.4)6 (3.6)155 (92.3)27 (16.1)97 (57.7)13 (7.7)10 (6)NANA3.7 (2.9,4.5)62 (49,75.1)NANANAZhao W et al. \[[@bib0245]\]2 (2.6)20 (26)16 (20.8)NANANANANANANANA64 (54,78)NANANAWang D et al. \[[@bib0250]\]5 (3.6)36 (26.1)6 (4.3)124 (89.9)62 (44.9)106 (76.81)15 (10.9)17 (12.3)4 (2.9)2 (1.45)4.4 (3.4,5.8)72 (60,87)NANANAZhang G et al. \[[@bib0255]\]10 (4.5)55 (24.9)12 (5.4)196 (88.7)115 (52.0)NA27 (12.2)16 (7.2)10 (4.5)5 (2.3)4.3 (3.4,5.6)69 (56,84)NANANAHu L et al. \[[@bib0260]\]17 (5.3)172 (53.3)NANA196 (60.7)NA105 (32.5)34 (10.5)NA72 (22.3)\>8 mmol/L 72 (22.3)\>144 μmol/L 7 (2.2)NANANAShi P et al. \[[@bib0265]\]3 (2.2)46 (34.2)1 (0.7)129 (96.3)41 (30.6)91 (67.9)2 (1.5)1 (0.7)1 (0.7)1 (0.7)3.6 (3.0, 4.5)60.0 (50.4, 73.0)NANANALi Z et al. \[[@bib0270]\]55 (28.5)65 (33.7)32 (17)187 (98)119 (62)182 (94)50 (26)33 (17)3 (2)7 (4)4.4 (3.22,6.44)66 (54,82)76 (59)57 (44)237 (185,302)Li Q et al. \[[@bib0275]\]19 (5.8)3 (0.9)26 (8)296 (91.1)69 (21.2)NA11 (3.4)15 (4.6)7 (2.2)3 (0.9)4.41 (3.55,5.45)63 (51,75)NANANAZhao XY et al. \[[@bib0280]\]5 (5.5)30 (33)2 (2.2)81 (89)79 (86.8)29 (31.9)NANANA3 (3.3)NA\>97 μmol/L 5 (5.5)NANA\>417 μmol/L 5 (5.5)Yang L et al. \[[@bib0285]\]24 (12)29 (14.5)15 (7.5)199 (99.5)112 (56)158 (79)35 (17.5)16 (8)NA2 (1)NA64 (52.5,83.1)NANANAYang Q et al. \[[@bib0290]\]4 (2.9)33 (24.3)23 (16.9)NANA66 (48.5)NA25 (18.4)NANA4 (3.2,5.4)67.9 (54.8,81.2)NANANAMichael G et al. \[[@bib0295]\]288/850 (33.9)236 (23.6)211 (21.1)NA178/850 (20.9)NANANA5/850 (0.6)NANANANANANAAntoni S et al. \[[@bib0300]\]8 (2.5)56 (17.4)NA131 (40.7)34 (10.6)86 (26.7)NANANANANANANANANAKyung Soo et al. \[[@bib0195]\]9 (9.2)13 (13.3)5 (5.197 (99)18 (18.4)37 (37.8)12 (12.2)11 (11.2)4 (4.1)3 (3.1)15.3 ± 9.5 mg/dL0.9 ± 0.5 mg/dLNANANA[^3]

3.1. Incidence of AKI {#sec0040}
---------------------

In this meta-analysis, there were 40 studies with 24,377 patients used to assess the incidence of AKI in COVID-19 patients \[[@bib0025],[@bib0065],[@bib0120], [@bib0125], [@bib0130], [@bib0135], [@bib0140], [@bib0145], [@bib0150], [@bib0155], [@bib0160], [@bib0165], [@bib0170], [@bib0175], [@bib0180], [@bib0185], [@bib0190], [@bib0195], [@bib0200], [@bib0205], [@bib0210], [@bib0215], [@bib0220], [@bib0225], [@bib0230], [@bib0235], [@bib0240], [@bib0245], [@bib0250], [@bib0255], [@bib0260], [@bib0265], [@bib0270], [@bib0275], [@bib0280], [@bib0285], [@bib0290], [@bib0295], [@bib0300], [@bib0305]\]. We found that the incidence of AKI was 10 % (95 % CI 8%--13 %) in COVID-19 patients, but there was evidence of statistical heterogeneity among the studies, with *I^2^* = 98 %. The meta-analysis also showed that the incidence of AKI was 15 % (95 % CI 9--24 %) and 9 % (95 % CI 7--11 %) internationally and in China, respectively ([Fig. 2](#fig0010){ref-type="fig"} A). The funnel plot including all studies according to their weights almost showed symmetry, indicating a high risk of publication bias (**τ** =-5.194, *P* \< 0.01, [Fig. 2](#fig0010){ref-type="fig"}B).Fig. 2Meta-analysis of incidence of AKI in COVID-19 infection.A. Forest plot of incidence of AKI in COVID-19 infection.B. Funnel plot of incidence of AKI in COVID-19 infection of publication bias.Fig. 2

The sensitivity analyses for the incidence of AKI produced trivial changes after the removal of each study individually. The incidence of AKI in the remaining studies was approximately 10 %, and the meta-analysis results were still robust (Supplementary material Fig. 1).

3.2. Risk of fatality {#sec0045}
---------------------

### 3.2.1. Fatality rate {#sec0050}

In this meta-analysis, there were 20 studies with 9,806 patients used to assess the fatality rate in COVID-19 patients with or without AKI, as shown in [Fig. 3](#fig0015){ref-type="fig"} A. The overall fatality rate was 20.3 %.Fig. 3Meta-analysis of fatality in COVID-19 patients with or without AKI.A. Forest plot of fatality in COVID-19 patients with or without AKI.B. Funnel plot of fatality for the assessment of publication bias.Fig. 3

Compared with patients with AKI, patients without AKI had a considerably lower fatality rate (12.9 % vs. 63.1 %, *P* \< 0.01), and AKI was significantly associated with increased fatality in patients with COVID-19 (OR = 14.63, 95 % CI: 9.94--21.51, *P* \< 0.00001, *I* ^2^ = 77 %, *P* \< 0.01). The funnel plot including all studies according to their weights showed symmetry, indicating a low risk of publication bias (**τ** = 0.3489, *P* = 0.73, [Fig. 3](#fig0015){ref-type="fig"}B).

The sensitivity analyses for the fatality rate in COVID-19 patients with or without AKI produced trivial changes after removal of each study individually, and the meta-analysis results were still robust (Supplementary material Fig. 2).

### 3.2.2. Serum levels of Scr and BUN in the fatality of COVID-19 infection {#sec0055}

A total of 8 studies including 2,138 COVID-19-infected patients (608 patients in the fatality group and 1,530 in the non-fatality group) were used to assess the relationship between Scr levels and fatality. Compared with the non-fatality group, the fatality group showed higher levels of Scr \[mean difference (MD): 20.19 μmol/L, 95 % CI: 14.96--25.42, *P* \< 0.00001, *I* ^2^ = 55 %, Cochran's *Q*, *P* = 0.03\] ([Fig. 4](#fig0020){ref-type="fig"} A). The funnel plot including all studies according to their weights showed symmetry, indicating a low risk of publication bias (**τ** = 0.3915, *P* = 0.77, [Fig. 4](#fig0020){ref-type="fig"}B).Fig. 4Meta-analysis of the association between Scr and BUN levels and fatality in COVID-19 patients.A. Forest plot of the association between levels of Scr and fatality in COVID-19 patients.B. Funnel plot of Scr levels and fatality for the assessment of publication bias.C. Forest plot for the association between serum levels of BUN and fatality in COVID-19 patients.D. Funnel plot of BUN serum levels and fatality for the assessment of publication bias.Fig. 4

A total of 5 studies including 1,458 COVID-19-infected patients (367 patients in the fatality group and 1,091 in the non-fatality group) were used to assess the relationship between serum blood urea nitrogen (BUN) levels and fatality. Compared with the non-fatality group, the fatality group had higher serum levels of BUN \[MD: 4.07 mmol/L, 95 % CI: 3.33--4.81, *P* \< 0.00001, *I* ^2^ = 46 %, Cochran's *Q*, *P* = 0.12\] ([Fig. 4](#fig0020){ref-type="fig"}C). The funnel plot including all studies according to their weights showed symmetry, indicating a high risk of publication bias (**τ** =-1.1917, *P* = 0.32, [Fig. 4](#fig0020){ref-type="fig"}D).

3.3. Risk of severe infection {#sec0060}
-----------------------------

### 3.3.1. Severity rate {#sec0065}

A meta-analysis with 12,557 patients from 24 published observational studies was performed for the rate of severe infection in COVID-19 patients with or without AKI ([Fig. 5](#fig0025){ref-type="fig"} A). In our study, the overall severity rate was 26.4 %.Fig. 5Meta-analysis of severe infection in COVID-19 patients with or without AKI.A. Forest plot of severe infection in COVID-19 patients with or without AKI.B. Funnel plot of severe infection for the assessment of publication bias.Fig. 5

Compared with patients without AKI, patients with AKI had a considerably higher severity rate (55.6 % vs. 17.7 %, *P* \< 0.01), and AKI was found to be associated with a nearly 8.11-fold significantly increased risk of severe infection in COVID-19 patients (*OR* = 8.11, 95 % CI: 5.01--13.13, *P* \< 0.00001, *I* ^2^ = 88 %, *P* \< 0.01). The funnel plot including all studies according to their weights showed symmetry, indicating a low risk of publication bias (**τ** = -0.2904, *P* = 0.77, [Fig. 5](#fig0025){ref-type="fig"}B).

The sensitivity analyses for the rate of severe infection in COVID-19 patients with or without AKI produced trivial changes after removal of each study individually, and the meta-analysis results were still robust (Supplementary material Fig. 3).

### 3.3.2. Serum levels of Scr and BUN in severe COVID-19 infection {#sec0070}

A total of 12 studies including 1,968 COVID-19-infected patients (551 patients in the severe group and 1417 in the non-severe group) were used to assess the relationship between the severity of infection and the levels of Scr. Compared with the non-severe group, the severe group had higher serum levels of Scr \[MD: 7.78 μmol/L, 95 % CI: 4.43--11.14, *P* \< 0.00001, *I* ^2^ = 34 %, Cochran's *Q*, *P* = 0.12\] ([Fig. 6](#fig0030){ref-type="fig"} A). The funnel plot including all studies according to their weights showed symmetry, indicating a low risk of publication bias (**τ** = 2.4416, *P* = 0.03, [Fig. 6](#fig0030){ref-type="fig"}B).Fig. 6Meta-analysis of the association between Scr and BUN levels and severe infection in COVID-19 patients.A. Forest plot of the association between serum levels of creatinine and severe infection in COVID-19 patients.B. Funnel plot of serum creatinine levels and severe infection for the assessment of publication bias.C. Forest plot of the association between serum blood urea nitrogen levels and severe infection in COVID-19 patients. D. Funnel plot of serum blood urea nitrogen levels and severe infection for the assessment of publication bias.Fig. 6

A total of 7 studies including 1,445 COVID-19-infected patients (303 patients in the severe group and 1,142 in the non-severe group) was used to assess the relationship between the severity of infection and the serum BUN levels. Compared with the non-severe group, the severe group had higher serum BUN levels \[MD: 2.12 mmol/L, 95 % CI: 1.74--2.50, *P* \< 0.00001, *I* ^2^ = 0%, Cochran's *Q*, *P* = 0.55\] ([Fig. 6](#fig0030){ref-type="fig"}C). The funnel plot including all studies according to their weights showed symmetry, indicating a low risk of publication bias (**τ** = -0.3816, *P* = 0.72, [Fig. 6](#fig0030){ref-type="fig"}D).

4. Discussion {#sec0075}
=============

Based on our meta-analysis of some early and preliminarily available data, COVID-19 patients with AKI had higher severe infection and case-fatality rates, and AKI was a risk factor associated with severe infection and fatality in patients with COVID-19. To our knowledge, this study is the first systematic review and meta-analysis to assess the association between AKI and the risk of severe disease and death in COVID-19 patients. Our study has shown that the incidence of AKI in COVID-19 patients was 10 %, mainly indicated by elevated Scr and BUN levels. We found that the BUN and Scr levels were significantly higher in severe infection patients than in non-severe patients, and these factors were significantly associated with the death of COVID-19 patients. This finding is consistent with results from previous studies, which confirmed that elevated Scr and BUN levels were independent risk factors for in-hospital death \[[@bib0065],[@bib0310],[@bib0315]\].

In our meta-analysis, the overall fatality rate was 20.3 %, and the severity rate was 26.4 %, which are much higher than the values of 3.1 % and 20.2 % reported in a recent meta-analysis including 53,000 patients, with COVID-19 is the largest sample size so far. So, this study should be largely representative of the rate of severe infection and fatality at large in COVID-19 patients \[[@bib0320]\]. A possible reason for the high fatality rate is that the included studies had a high proportion of severely infected patients. This large sample size report also showed that the case-fatality rate was associated with disease severity, as all cases of death involved critical patients \[[@bib0035]\]. Another possible reason is different from study\'s searching strategy. Our study focuses on severe infection and fatality of acute kidney injury in COVID-19, It could overestimate the rate of severe infection and fatality. According to a recent study, AKI in COVID-19 patients was associated with a higher risk of death even after adjustment for potential confounders \[[@bib0065]\]. Therefore, the existence of AKI should be regarded as an important index in the risk stratification of disease severity and death for COVID-19 patients, and risk screening contributes to early intervention to reduce the incidence or progression of AKI.

4.1. Pathophysiology of AKI {#sec0080}
---------------------------

The detailed pathophysiologic relationship between COVID-19 and AKI remains unclear. SARS-CoV-2 causes kidney injury through direct and indirect pathogenic pathways \[[@bib0325]\]. First, the novel coronavirus may exert direct cytopathic effects on kidney tissue \[[@bib0330]\]. Online datasets and bioinformatic analyses identified that angiotensin-converting enzyme 2 (ACE2), one of the major receptors of SARS-CoV-2, is highly expressed in renal cells, particularly in tubular cells \[[@bib0335],[@bib0340]\]. A recent report analyzed the histology of renal tissues from autopsies and found acute renal tubular damage in six COVID-19 cases, and human tissue RNA-sequencing data demonstrated that ACE2 expression in the kidney was nearly 100-fold higher than that in the lung \[[@bib0345],[@bib0350]\]. Therefore, SARS-CoV-2 could enter renal tubular cells by binding to ACE2, which induces cytotoxicity and leads to abnormal renal function \[[@bib0270],[@bib0335]\]. Second, SARS-CoV-2 infection may also cause kidney injury through overactivation of the immune system, with the release of a large number of cytokines and cytokine storms \[[@bib0355]\]. Third, COVID-19 patients with severe infections often have low blood pressure, dehydration, hypoxemia, electrolyte acid-base imbalances, acute heart failure and viremia, which have all been implicated in AKI \[[@bib0040]\]. In addition, most COVID-19 patients with AKI are older and have frequent comorbidities such as hypertension or diabetes mellitus; these factors are well-known factors of renal vulnerability \[[@bib0360]\]. Nephrotoxic drugs can also be influential in AKI development, especially antibiotics, antiviral medications and traditional medicines. However, these factors have been poorly investigated in COVID-19 patients.

4.2. Treatment of COVID-19-induced AKI {#sec0085}
--------------------------------------

Based on these results, we should focus more attention on kidney damage at the early stage when patients are confirmed to be infected by COVID-19. Clinicians should longitudinally and dynamically measure kidney damage biomarkers, such as the fluctuation of Scr and BUN levels with respect to volume and hemodynamic status, during in-hospital SARS-CoV-2 infection, which may help to identify a subset of patients with AKI, especially in elderly patients, in combination with noting whether the patient has a past history of hypertension, coronary heart disease and chronic kidney disease; moreover, these measures should also be taken in patients admitted to the intensive care unit. Risk screening could predict the progression of COVID-19 to minimize patients' in-hospital fatality and improve their long-term prognosis.

To date, there is no specific treatment for COVID-19-induced AKI. The treatment of AKI is aimed at addressing the underlying causes of AKI. Therefore, antiviral drugs and immunomodulatory drugs are the primary modes of management for AKI in COVID-19 \[[@bib0360]\]. However, several older drugs, such as diuretics, acetylcysteine and sodium bicarbonate, are used to treat AKI in COVID-19 \[[@bib0365]\]. Alternatively, traditional Chinese medications (Bailing Granules) and Chinese herbal medicine are also used to treat AKI in COVID-19 \[[@bib0370]\]. If conservative management fails, CRRT should be considered in patients with volume overload, especially those with refractory hypoxemia. For COVID-19 patients with a high risk, blood volume and hemodynamics should be optimized to ensure adequate, effective renal perfusion pressure, and the use of nephrotoxic drugs should be avoided. In the event of signs of AKI, potential interventions, including continuous renal replacement therapy, should be used to protect renal function as early as possible \[[@bib0050]\].

4.3. Limitations {#sec0090}
----------------

This study has several limitations. First, the COVID-19 patients in our meta-analysis had a high case-fatality rate, which may be due to them being early reports from early stages of the outbreak and involving a higher proportion of severely ill patients. Therefore, the relationship between AKI and fatality risk in mildly ill patients still needs to be evaluated. Second, most studies were not adjusted for various confounding factors, which might have caused bias in the results. Third, all included studies were retrospective, and there was a risk of bias in the data collected. At the same time, the quality of different studies varied, which might lead to bias. As the disease spreads around the world, it is hoped that other countries affected by COVID-19 will report more clinical data to verify our results. Finally, we have diligently and carefully tried to go through each included article's study setting and author list to avoid overlapping patient data. However, in our large meta-analysis of 24,527 patients, the small overlapping patient data of the same centers of Wuhan, China is inevitable and inconsequential.

5. Conclusion {#sec0095}
=============

In conclusion, AKI is a crucial complication in patients with COVID-19, and it may be related to a higher risk of severe infection and poor prognosis. Special care and monitoring are needed in COVID-19 patients with AKI to reduce the risk of severe infection and improve prognosis.
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[^2]: Data are presented as means ± SD, n (%) or median (interquartile range).No. of patients, number of COVID-19 confirmed patients; NOS, the Newcastle-Ottawa Scale; COPD, chronic obstructive pulmonary disease; CVD, Cardiovascular diseases; CKD, chronic kidney disease; NA, data not available.

[^3]: Data are presented as means ± SD, n (%) or median (interquartile range). AKI, Acute kidney injury; CFR, case fatality rate; CSR, case severity rate; NA, data not available; NIV, non-invasive ventilation; IMV, invasive mechanical ventilation; ECMO: extracorporeal membrane oxygenation; CRRT, continuous renal replacement therapy; UA, Uric acid; BUN, Blood urea nitrogen; Scr, Serum creatinine.
